LY-2623091

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameLY-2623091
Drug Alias NameLY-2623091
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor antagonists
TargetsMineralocorticoid receptor
Therapy Area/IndicationsEssential HypertensionRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsEssential HypertensionRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksN/A